Dr. Hilal Ahmad Parray is currently a postdoctoral fellow at UT Southwestern Medical Center in Texas, USA. He obtained his PhD in Biotechnology from Daegu University, South Korea in 2018. Dr. Parray has a diverse professional background, having served as a Postdoctoral Fellow at Niigata National University in Japan and Translational Health Science and Technology Institute in India between 2018 and 2021. His specialization lies in the field of antibody engineering, utilizing hybridoma and phage display technology. Dr. Parray has a wealth of experience and is an expert in the field of monoclonal antibody-based medicinal development. His current work is mostly focused on advancing the development of antibody-based treatments, with an emphasis on viruses as dangerous pathogens. With over 40 research publications in esteemed international journals, including renowned publications such as Nature Microbiology, Dr. Parray has gained widespread recognition as a pioneering figure in his field. Dr. Rajesh Kumar is Assistant Professor in the Department of Biosciences, Himachal Pradesh University, India. He obtained his MSc and PhD in Zoology from Jiwaji University, India. Dr. Kumar’s research focuses on animal physiology, applied zoology, biodiversity conservation, nutraceuticals, herbal medicine, and cancer biology. He brings a decade of research and teaching experience to this project and has participated in several book projects, including Elsevier’s Advanced Techniques in Antibody Generation and Diabetes, Aging, and Management Strategies. Dr. Irfan A. Rather is a highly accomplished academic and researcher currently serving as an Associate Professor at King Abdulaziz University in Jeddah. Prior to this, he held the position of Assistant Professor at Yeungnam University. Throughout his career, Dr. Rather has published over 100 scientific papers in reputable journals and holds ten patents, making him a widely recognized innovator in his field. Dr. Rather's research focuses on two key areas: understanding the pathogenesis of zoonotic viruses and investigating the role of the gut microbiome in immune modulation. His extensive expertise and in-depth knowledge have enabled him to make significant contributions to these critical areas of research, helping to advance our understanding of these complex and challenging topics. Dr. Rather is widely respected in the scientific community for his contributions, which have been recognized for their exceptional quality and impact.

• 1. Antibody engineering recent advances: From discovery to clinical applications2. Mechanisms and purposes of immunogen-induced antibody production in different hosts3. Methods and applications for antibody screening and optimization4. Immunoglobulin molecules: Structure, function, and applications5. Therapeutic and diagnostic applications of antibody-based strategies for precision medicine6. Targeted drug delivery using antibodies: Concepts, methods, and applications7. Hybridoma, monoclonal antibody technology8. Optimizing therapeutic antibodies through glyco-engineering9. Applications of hybridoma-based monoclonal antibodies in therapeutics research and diagnostics10. Engineering and applications of bispecific and multi-specific antibodies11. Hybridoma technology in the biotechnology industry: Current status and future trends12. Bacteriophage display technology or phage display technology13. Antibody engineering using phage display, yeast display and ribosome display14. Phage display in cancer research and vaccine development15. Diagnostic and therapeutic applications of phage display16. Phage display technology in the biotechnology industry: Current status and future trends directions

Dr. Hilal Ahmad Parray is currently a postdoctoral fellow at UT Southwestern Medical Center in Texas, USA. He obtained his PhD in Biotechnology from Daegu University, South Korea in 2018. Dr. Parray has a diverse professional background, having served as a Postdoctoral Fellow at Niigata National University in Japan and Translational Health Science and Technology Institute in India between 2018 and 2021. His specialization lies in the field of antibody engineering, utilizing hybridoma and phage display technology. Dr. Parray has a wealth of experience and is an expert in the field of monoclonal antibody-based medicinal development. His current work is mostly focused on advancing the development of antibody-based treatments, with an emphasis on viruses as dangerous pathogens. With over 40 research publications in esteemed international journals, including renowned publications such as Nature Microbiology, Dr. Parray has gained widespread recognition as a pioneering figure in his field. Dr. Rajesh Kumar is Assistant Professor in the Department of Biosciences, Himachal Pradesh University, India. He obtained his MSc and PhD in Zoology from Jiwaji University, India. Dr. Kumar’s research focuses on animal physiology, applied zoology, biodiversity conservation, nutraceuticals, herbal medicine, and cancer biology. He brings a decade of research and teaching experience to this project and has participated in several book projects, including Elsevier’s Advanced Techniques in Antibody Generation and Diabetes, Aging, and Management Strategies. Dr. Irfan A. Rather is a highly accomplished academic and researcher currently serving as an Associate Professor at King Abdulaziz University in Jeddah. Prior to this, he held the position of Assistant Professor at Yeungnam University. Throughout his career, Dr. Rather has published over 100 scientific papers in reputable journals and holds ten patents, making him a widely recognized innovator in his field. Dr. Rather's research focuses on two key areas: understanding the pathogenesis of zoonotic viruses and investigating the role of the gut microbiome in immune modulation. His extensive expertise and in-depth knowledge have enabled him to make significant contributions to these critical areas of research, helping to advance our understanding of these complex and challenging topics. Dr. Rather is widely respected in the scientific community for his contributions, which have been recognized for their exceptional quality and impact.

• 1. Antibody engineering recent advances: From discovery to clinical applications2. Mechanisms and purposes of immunogen-induced antibody production in different hosts3. Methods and applications for antibody screening and optimization4. Immunoglobulin molecules: Structure, function, and applications5. Therapeutic and diagnostic applications of antibody-based strategies for precision medicine6. Targeted drug delivery using antibodies: Concepts, methods, and applications7. Hybridoma, monoclonal antibody technology8. Optimizing therapeutic antibodies through glyco-engineering9. Applications of hybridoma-based monoclonal antibodies in therapeutics research and diagnostics10. Engineering and applications of bispecific and multi-specific antibodies11. Hybridoma technology in the biotechnology industry: Current status and future trends12. Bacteriophage display technology or phage display technology13. Antibody engineering using phage display, yeast display and ribosome display14. Phage display in cancer research and vaccine development15. Diagnostic and therapeutic applications of phage display16. Phage display technology in the biotechnology industry: Current status and future trends directions

Dr. Hilal Ahmad Parray is currently a postdoctoral fellow at UT Southwestern Medical Center in Texas, USA. He obtained his PhD in Biotechnology from Daegu University, South Korea in 2018. Dr. Parray has a diverse professional background, having served as a Postdoctoral Fellow at Niigata National University in Japan and Translational Health Science and Technology Institute in India between 2018 and 2021. His specialization lies in the field of antibody engineering, utilizing hybridoma and phage display technology. Dr. Parray has a wealth of experience and is an expert in the field of monoclonal antibody-based medicinal development. His current work is mostly focused on advancing the development of antibody-based treatments, with an emphasis on viruses as dangerous pathogens. With over 40 research publications in esteemed international journals, including renowned publications such as Nature Microbiology, Dr. Parray has gained widespread recognition as a pioneering figure in his field. Dr. Rajesh Kumar is Assistant Professor in the Department of Biosciences, Himachal Pradesh University, India. He obtained his MSc and PhD in Zoology from Jiwaji University, India. Dr. Kumar’s research focuses on animal physiology, applied zoology, biodiversity conservation, nutraceuticals, herbal medicine, and cancer biology. He brings a decade of research and teaching experience to this project and has participated in several book projects, including Elsevier’s Advanced Techniques in Antibody Generation and Diabetes, Aging, and Management Strategies. Dr. Irfan A. Rather is a highly accomplished academic and researcher currently serving as an Associate Professor at King Abdulaziz University in Jeddah. Prior to this, he held the position of Assistant Professor at Yeungnam University. Throughout his career, Dr. Rather has published over 100 scientific papers in reputable journals and holds ten patents, making him a widely recognized innovator in his field. Dr. Rather's research focuses on two key areas: understanding the pathogenesis of zoonotic viruses and investigating the role of the gut microbiome in immune modulation. His extensive expertise and in-depth knowledge have enabled him to make significant contributions to these critical areas of research, helping to advance our understanding of these complex and challenging topics. Dr. Rather is widely respected in the scientific community for his contributions, which have been recognized for their exceptional quality and impact.

• 1. Antibody engineering recent advances: From discovery to clinical applications2. Mechanisms and purposes of immunogen-induced antibody production in different hosts3. Methods and applications for antibody screening and optimization4. Immunoglobulin molecules: Structure, function, and applications5. Therapeutic and diagnostic applications of antibody-based strategies for precision medicine6. Targeted drug delivery using antibodies: Concepts, methods, and applications7. Hybridoma, monoclonal antibody technology8. Optimizing therapeutic antibodies through glyco-engineering9. Applications of hybridoma-based monoclonal antibodies in therapeutics research and diagnostics10. Engineering and applications of bispecific and multi-specific antibodies11. Hybridoma technology in the biotechnology industry: Current status and future trends12. Bacteriophage display technology or phage display technology13. Antibody engineering using phage display, yeast display and ribosome display14. Phage display in cancer research and vaccine development15. Diagnostic and therapeutic applications of phage display16. Phage display technology in the biotechnology industry: Current status and future trends directions